Telehealth company Hims & Hers Health has been placed in Visa's Acquirer Monitoring Program (AMP) after a surge in customer payment disputes, according to a Bloomberg report citing internal documents. The move follows a jump in chargebacks—the industry term for when a cardholder disputes a charge and the payment is reversed—related to the company's weight-loss subscription service.
Bloomberg reported that Stripe, a major payments processor, informed Hims earlier this month about the Visa action. The immediate financial hit is modest: Visa charges a fee of $8 per disputed transaction, which Bloomberg says amounts to nearly $75,000 for September. But the bigger concern for investors is what the monitoring program signals about the company's operations and customer satisfaction.
What is the Acquirer Monitoring Program?
Visa's AMP is a compliance mechanism designed to flag merchants with chargeback rates that exceed certain thresholds. When a merchant is placed in the program, they are typically required to submit a remediation plan and may face higher fees or additional oversight until the issue is resolved. The program is meant to protect cardholders and the payment ecosystem from merchants with problematic billing practices.
For Hims, the trigger appears to be a spike in disputes tied to its weight-loss subscriptions, which have become a major growth driver for the company. The service, which offers GLP-1 medications and other weight-loss treatments, has attracted significant customer interest but also complaints about billing and subscription renewals.
Being in AMP is not a permanent status. Merchants can exit once they demonstrate that chargeback rates have fallen below Visa's thresholds for a sustained period. However, the process can take months, and during that time the company may face additional scrutiny from its payment processor and card networks.
What it means for Hims & Hers
The $75,000 fee is a rounding error for a company that generates hundreds of millions in quarterly revenue. But the underlying issue—customer disputes—could signal deeper problems. Chargebacks often stem from customers feeling they were charged without consent, or from confusion about subscription terms. For a subscription-based business, high chargeback rates can erode trust and lead to higher customer acquisition costs.
Hims has not publicly commented on the Bloomberg report. The company has previously said it works to address customer concerns and maintain transparent billing practices. Still, the news adds a layer of risk to a stock that has been volatile, especially as competition in the weight-loss drug space intensifies.
Investors should watch how Hims responds. If the company can quickly reduce chargebacks and exit AMP, the impact will likely be minimal. But if disputes persist, it could lead to higher processing fees, potential restrictions on card acceptance, or even damage to its brand reputation.
Broader context for investors
This story fits into a larger pattern of regulatory and operational scrutiny facing telehealth and direct-to-consumer healthcare companies. As these firms grow rapidly, they often face challenges in managing customer expectations and billing practices. For everyday investors, it's a reminder that subscription-based businesses carry unique risks—especially when they involve recurring charges that customers may not always remember or understand.
Chargebacks are not unique to Hims. Many online merchants, from streaming services to meal-kit companies, deal with disputes. But the scale and speed of Hims' growth in weight-loss treatments has put it under a microscope. The company's stock has been a favorite among retail investors, and any news that raises questions about its operational stability can move the share price.
Looking ahead, investors will likely monitor Hims' next earnings report for any mention of chargeback rates or changes in payment processing. They may also watch for updates on how the company plans to address the issue. In the meantime, the news serves as a cautionary tale about the hidden costs of rapid expansion.
For those interested in the broader market, this development comes amid a busy earnings season, with heavyweights reporting results and AI companies facing rising debt costs. But for Hims investors, the immediate focus is on whether the company can clean up its billing practices and move past this setback.
